InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...
Cytochrome P450 CYP121A1 is a pivotal enzyme in Mycobacterium tuberculosis, playing an essential role in the biosynthesis of mycocyclosin via a phenol coupling reaction of the dipeptide ...
Tyrosine kinase inhibitors (TKIs) are metabolized via the cytochrome P450 pathway, which may be associated with the production of toxic intermediates. These drugs can also induce oxidative stress and ...
Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in patients with metastatic colorectal cancer (mCRC). This is an ASCO Meeting Abstract from the 2011 ASCO ...
Guangzhou Vinnocent Pharmaceutical Ltd. has divulged cytochrome P450 11B1, mitochondrial (CYP11B1; steroid 11-β-monooxygenase) and cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ...
Gut microbiome alterations in breast cancer survivors with cancer-related fatigue. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not include a full text ...
An interdisciplinary research team at The University of Texas at San Antonio has successfully developed an innovative inhibitor that shows promise in fighting obesity and potentially preventing heart ...